Prostamax

Prostamax is Lys-Glu-Asp-Pro, held by the US National Library of Medicine as lysyl-glutamyl-aspartyl-proline. Six PubMed records name it, and all six are biophysics or cytogenetics papers about chromatin in human lymphocytes. Not one concerns the prostate gland.

The prostate branding therefore asserts the developers' organ-matching theory rather than summarising findings.

The published mechanism is chromatin decondensation. In cultured lymphocytes from donors aged 75–86, KEDP raised sister chromatid exchange to 12.0 ± 0.28 per cell against 5.9 ± 0.2 untreated, increased silver-positive nucleolar organiser regions to 2.5 per cell from 0.95, and shrank the pericentromeric heterochromatin blocks on chromosomes 1 and 9 ( Dzhokhadze et al., Georgian Med News 2012;(212):76-82, in Russian). An earlier microcalorimetry study reported the peptide shifting lymphocyte thermal denaturation endotherms downward by 2.9°C and 1.0°C, read as partial relaxation of the chromatin fibre ( Meskhi et al., Biofizika 2004, in Russian).

Both are real measurements; neither is a prostate measurement. And increased sister chromatid exchange is conventionally read as a marker of genomic instability, not of rejuvenation.

Benign prostatic hyperplasia, prostatitis and prostate cancer have established diagnostic pathways; KEDP is absent from all of them. The practical hazard is delay — urinary symptoms and a rising PSA are findings that need evaluation, and self-managing them with an unstudied compound postpones it.

The S0 provision still reaches unapproved pharmacological substances as a class, and nothing about this peptide has been reviewed by an anti-doping science panel. A direct enquiry to the relevant national organisation is the only safe route.

No safety study of KEDP exists in humans or animals. One indexed paper used it in a microcalorimetric experiment alongside copper and cadmium salts on lymphocytes ( Georgian Med News 2009) — a toxicology-adjacent design that was not a toxicology study. There is no basis for a side-effect profile.

Every published exposure to KEDP happened in a test tube. No route, systemic concentration, half-life or clearance figure has been reported for a living human, so this page offers no quantities or schedules.

Distributed as a lyophilised powder within the organ-named range. Because Prostatilen is a licensed product in some post-Soviet markets while KEDP is not, listings that blur the two imply a regulatory standing this peptide lacks.

The file is essentially the output of one Tbilisi cytogenetics group publishing in Georgian Medical News, Biofizika and Bulletin of Experimental Biology and Medicine between 2004 and 2017. Sample sizes are cell counts, not participants. No independent laboratory has attempted a replication, and no study has looked at prostate tissue, urinary symptoms or PSA.

For deeper dives on this peptide, see:

• Prostamax benefits and areas of interest
• Prostamax side effects and safety context
• Prostamax dosing concepts (educational)
• Prostamax research and evidence overview

Is there any evidence Prostamax affects the prostate? None has been published; every indexed study used lymphocytes in culture. The prostate association is a naming convention from the bioregulator theory, untested by experiment.

How is Prostamax different from Prostatilen? Prostamax is a chemically defined synthetic tetrapeptide; Prostatilen is a mixture extracted from animal prostate tissue and registered as a medicine in some post-Soviet countries. They share a marketing niche and nothing else.

Why do researchers call this evidence weak? Chromatin staining in a dish is a surrogate for a surrogate: the studies measure whether chromosomes look looser, infer gene activation, then infer a benefit nobody measured — from one research network, in one city, with no replication.

Is it approved by any regulator? No. It has no marketing authorisation from the FDA, EMA or MHRA and is sold as a research chemical.